2-amino-5-phosphonovalerate has been researched along with neurotensin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Helmstetter, FJ; Tershner, SA | 1 |
Bonci, A; Cho, SL; de Lecea, L; Deisseroth, K; Kempadoo, KA; Leinninger, GM; Magnani, F; Myers, MG; Stuber, GD; Tourino, C; Zhang, F | 1 |
2 other study(ies) available for 2-amino-5-phosphonovalerate and neurotensin
Article | Year |
---|---|
Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray.
Topics: Amygdala; Analgesics, Opioid; Animals; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Male; Naltrexone; Narcotic Antagonists; Neural Pathways; Neurons; Neurotensin; Nociceptors; Pain; Peptides; Periaqueductal Gray; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Opioid, delta; Receptors, Opioid, mu; Time Factors; Valine | 2000 |
Hypothalamic neurotensin projections promote reward by enhancing glutamate transmission in the VTA.
Topics: Animals; Bacterial Proteins; Channelrhodopsins; Conditioning, Operant; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Glutamic Acid; Hypothalamus; In Vitro Techniques; Light; Luminescent Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Neural Pathways; Neurotensin; Pyrazoles; Quinolines; Quinoxalines; Receptors, Neurotensin; Reward; Self Stimulation; Signal Transduction; Tyrosine 3-Monooxygenase; Valine; Ventral Tegmental Area | 2013 |